Tivicay (dolutegravir) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  
 26 Diseases   58 Trials   58 Trials   4692 News 


«12...2930313233343536373839...6263»
  • ||||||||||  Journal:  The Use of Integrase Strand Transfer Inhibitors to Treat HIV in Pregnancy. (Pubmed Central) -  Aug 20, 2021   
    Here, we present the case of a pregnant woman with well-controlled HIV on a well-tolerated prepregnancy regimen of bictegravir, emtricitabine, and tenofovir alafenamide...In the second trimester, because of adverse effects from the new ART regimen and after a risk-benefit discussion, the patient restarted the original regimen. She was able to maintain viral suppression until giving birth.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion date, Trial primary completion date:  DoRIS: Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin (clinicaltrials.gov) -  Aug 18, 2021   
    P4,  N=36, Not yet recruiting, 
    Recruiting --> Completed | N=75 --> 37 | Trial completion date: Dec 2021 --> Aug 2021 | Trial primary completion date: Dec 2021 --> Aug 2021 Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Mar 2022 --> Oct 2022
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Phase classification, Enrollment change, Trial termination:  Dolutegravir in Reservoirs (clinicaltrials.gov) -  Aug 17, 2021   
    P4,  N=22, Terminated, 
    Phase classification: P=N/A --> P4 | N=40 --> 22 | Suspended --> Terminated; This study terminated early due to the ongoing covid-19 pandemic making it unsafe to recruit participants for in-person visits. Participants are living with HIV who are antiretroviral therapy-naive and are at high risk of COVID-19 complications.
  • ||||||||||  Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, Review, Journal:  Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis. (Pubmed Central) -  Aug 10, 2021   
    For virologic suppression at 48 weeks, odds ratios (95% credible intervals) were 0.6 (0.43, 0.82) for EFV+ tenofovir disoproxil fumarate (TDF)+emtricitabine (FTC) versus DTG+ abacavir+ lamivudine (3TC) and 0.52 (0.36, 0.75) for EFV+TDF+FTC vs. DTG+TDF+FTC/3TC...Outcomes associated with death were unsuitable for network meta-analysis due to low event rates. 3-drug regimens containing INI demonstrate better efficacy and safety than those containing RPV or EFV.
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
    Enrollment closed:  ALTAR: Reducing Antiretroviral Treatments (clinicaltrials.gov) -  Aug 9, 2021   
    P3,  N=360, Active, not recruiting, 
    3-drug regimens containing INI demonstrate better efficacy and safety than those containing RPV or EFV. Not yet recruiting --> Active, not recruiting
  • ||||||||||  Tybost (cobicistat) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
    Clinical, Journal:  Residual viremia in HIV-infected patients who continue a 2-drug or switch to a 3-drug integrase strand transfer inhibitor-based regimen. (Pubmed Central) -  Aug 8, 2021   
    In this randomized, single-center, open-label, 96-week, superiority, controlled trial of 50 HIV-infected patients with HIV-RNA <50 copies/mL on a two-drug regimen based on dolutegravir plus one reverse transcriptase inhibitor, switching to a single tablet regimen of cobicistat, elvitregravir, emtricitabine plus tenofovir alafenamide did not appear to mitigate the burden of residual viremia, both at week 48 and at week 96. The immunological changes observed during follow-up and the safety of the two regimens were similar.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma. (Pubmed Central) -  Aug 7, 2021   
    The median ratio of the drug concentration in saliva to those in plasma was 0.0056, which is close to the rate of non-protein-bound DTG in plasma (0.70%), suggesting that only free DTG in plasma is transported to the salivary glands and secreted into saliva. The present study demonstrates that DTG concentration in saliva reflects the pharmacologically active drug concentration in plasma and may provide an easily accessible alternative for monitoring effective antiretroviral treatment.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Vemlidy (tenofovir alafenamide) / Gilead
    Clinical, Journal:  Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV. (Pubmed Central) -  Aug 6, 2021   
    P3
    The present study demonstrates that DTG concentration in saliva reflects the pharmacologically active drug concentration in plasma and may provide an easily accessible alternative for monitoring effective antiretroviral treatment. The single-tablet regimen B/F/TAF is a safe, effective option for people virologically suppressed on DTG plus either F/TDF or F/TAF, including in individuals with pre-existing resistance to NRTIs.
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
    Clinical, Journal:  Weight gain in HIV-infected individuals using distinct antiretroviral drugs. (Pubmed Central) -  Aug 5, 2021   
    Ultimately, the development of overweight and obesity in an aging HIV population may increase the risk of cardiovascular events and should be prevented. In this scenario, the differential influence on weight gain using distinct antiretroviral agents might provide an opportunity for personalized medicine, adapting the most convenient drug regimen to each patient.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Enrollment open:  Patients' Experiences and Perceptions of 3TC/DTG Dual Therapy (the PEDAL Study) (clinicaltrials.gov) -  Aug 2, 2021   
    P=N/A,  N=120, Recruiting, 
    The versatility of this technology makes it attractive as an ULA drug delivery platform for HIV and various therapeutic applications. Not yet recruiting --> Recruiting
  • ||||||||||  bictegravir (GS-9883) / Gilead
    Clinical, Review, Journal:  HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety. (Pubmed Central) -  Jul 28, 2021   
    The newest INSTI, cabotegravir, represents an alternative to oral administration of life-long antiretroviral therapy with the availability of a long-acting injectable formulation. This review summarizes the current use of INSTIs in adults living with HIV, highlighting the similarities and differences within the class related to pharmacodynamics, pharmacokinetics, safety, dosing, and administration that contribute to their role in modern antiretroviral therapy.
  • ||||||||||  Selzentry (maraviroc) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion:  Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND) (clinicaltrials.gov) -  Jul 9, 2021   
    P4,  N=191, Completed, 
    Therefore, designing effective mechanisms to maintain virological suppression is important. Active, not recruiting --> Completed
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    [VIRTUAL] Update on neural tube defects with antiretoviral exposure in the Tsepamo study, Botswana () -  Jul 8, 2021 - Abstract #IASHIV2021IAS_HIV_1785;    
    Among those on second-line DTG, there was no new NRTI resistance, however 4 children developed new INSTI resistance, highlighting the need for ongoing adherence support among children starting second-line ART. The prevalence of NTDs among infants born to women on dolutegravir at conception has declined slightly to 0.15%, a non-significant difference from those exposed to non-dolutegravir antiretrovirals at conception
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, GSK3640254 / ViiV Healthcare
    Trial completion date, Trial primary completion date, Combination therapy:  DOMINO: A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults (clinicaltrials.gov) -  Jul 8, 2021   
    P2b,  N=150, Recruiting, 
    The prevalence of NTDs among infants born to women on dolutegravir at conception has declined slightly to 0.15%, a non-significant difference from those exposed to non-dolutegravir antiretrovirals at conception Trial completion date: Apr 2028 --> Aug 2028 | Trial primary completion date: Feb 2022 --> Jun 2022